-
Cathepsin Inhibitor
Z-Phe-Phe-Diazomethylketone is a selective inhibitor of cathepsin L, a cysteine protease involved in various cellular processes. This compound exhibits significant inhibitory activity toward cathepsin L, making it valuable in studies related to protein degradation, apoptosis, and various pathological conditions such as cancer and inflammation. It is useful for research applications that require modulation of proteolytic pathways involving cathepsins. -
Cat K Inhibitor
Cathepsin K inhibitor 6 is a potent small molecule specifically targeting cathepsin K (Cat K) with an IC50 value of 17 nM. In addition to its primary activity, it also demonstrates inhibitory effects on cathepsin L and cathepsin B, with IC50 values of 0.05 μM and 0.3 μM, respectively. This compound is valuable for studying bone resorption, fibrosis, and various pathological conditions associated with cathepsin activity. -
Cathepsin D/E FRET Substrate
Cathepsin D and E FRET Substrate is a fluorogenic substrate specifically designed for the selective detection of cathepsins D and E, avoiding interaction with cathepsins B, H, and L. Cleavage occurs at the Phe-Phe amide bond, releasing a fluorescent signal that can be quantitatively measured. This substrate is ideal for routine assays and mechanistic studies, facilitating the investigation of cathepsin activity in various biological contexts. -
Cathepsin D Substrate
Ac-Glu-Asp(EDANS)-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Gly-Lys(DABCYL)-Glu-NH2 is a specific substrate for cathepsin D, designed for use in fluorescence resonance energy transfer (FRET) assays. This compound exhibits key biological activity by releasing a detectable fluorescence signal upon cathepsin D cleavage, facilitating the study of proteolytic activity. It is valuable for investigating the role of cathepsin D in various biological processes and for screening potential inhibitors in drug development. -
Cathepsin
Z-Leu-Tyr-Chloromethylketone is a potent inhibitor of cathepsins, a family of cysteine proteases involved in various cellular processes. This compound exhibits significant inhibitory activity, making it valuable for studies related to protein degradation and apoptotic signaling pathways. It is applicable in research exploring the roles of cathepsins in diseases such as cancer and neurodegeneration. -
Cathepsin G Substrate
Suc-Val-Pro-Phe-pNA functions as a substrate specifically for cathepsin G. This compound allows for the quantitative assessment of cathepsin G activity, which is crucial for understanding its role in various physiological and pathological processes. Its application includes enzyme activity assays in research focused on inflammation, immune response, and other related biological pathways. -
Cathepsin K Inhibitor
Cathepsin K inhibitor 2 is a selective inhibitor targeting cathepsin K, a cysteine protease implicated in collagen degradation and bone remodeling. Inhibition of cathepsin K is particularly relevant in the study of osteoporosis and osteoarthritis, as it plays a crucial role in these conditions. This compound provides a valuable tool for researchers investigating the molecular mechanisms underlying bone-resorptive diseases and developing potential therapeutic strategies. -
Cathepsin L Inhibitor
RKLLW-NH2 is a selective inhibitor of Cathepsin L, a cysteine protease involved in various physiological and pathological processes. This compound exhibits significant inhibitory activity, making it a valuable tool for research focused on cancer, inflammation, and autoimmune diseases. RKLLW-NH2 may aid in elucidating the role of Cathepsin L in different biological pathways and conditions. -
Cathepsin B Inhibitor
Ac-Leu-Val-Lys-Aldehyde is a highly effective inhibitor of cathepsin B, demonstrating an IC50 of 4 nM. This compound exhibits significant neuroprotective activity by reducing quinolinic acid-induced striatal cell death and promoting the accumulation of LC3-II, a marker associated with autophagy. It serves as a valuable tool for investigating the role of cathepsin B in various biological processes and potential therapeutic strategies for neurodegenerative diseases. -
Cathepsin C Inhibitor
Cathepsin C-IN-4 is a selective inhibitor targeting Cathepsin C, demonstrating a potent inhibitory activity with an IC50 of 65.6 nM. In addition to its primary action, Cathepsin C-IN-4 exhibits significant inhibition in THP-1 and U937 cell lines with IC50 values of 203.4 nM and 177.6 nM, respectively. This compound is valuable for studies exploring the role of Cathepsin C in various biological processes and associated diseases. -
Cathepsin S Inhibitor
JNJ 10329670 is a selective noncovalent inhibitor of cathepsin S, exhibiting a Ki value of 34 nM for human cathepsin S. This compound effectively inhibits invariant chain proteolysis in B cells and dendritic cells, leading to the modulation of antigen-induced T cell proliferation. It serves as a valuable tool in immunological research and studies focused on autoimmune diseases and cancer immunotherapy. -
Cathepsin K Inhibitor
Cathepsin K Inhibitor 3 is a highly selective inhibitor targeting cathepsin K, demonstrating an IC50 value of 0.5 nM. This compound exhibits a favorable pharmacokinetic profile, making it suitable for research applications in osteoarthritis studies. Its specific action on cathepsin K positions it as a valuable tool in elucidating the role of this enzyme in bone resorption and related conditions. -
Cathepsin L Inhibitor
CLIK-148 is a highly selective, irreversible inhibitor of Cathepsin L, a cysteine protease known for its role in protein degradation. This compound effectively prevents the Cathepsin L-mediated degradation of HMG-CoA reductase within the endoplasmic reticulum and inhibits the processing of proCCK, subsequently reducing CCK8 production. CLIK-148 also impairs the breakdown of type I collagen by osteoclast-secreted Cathepsin L, thereby mitigating tumor-induced bone metastasis and hypercalcemia. This compound is valuable for investigating bone metabolism disorders and neuropeptide processing regulation. -
Cathepsin B Substrate
Z-Arg-Arg-4MβNA triacetate is a specific substrate for cathepsin B, designed to facilitate the study of this cysteine protease. Upon cleavage by cathepsin B, it generates the fluorescent product 4MβNA, which exhibits excitation and emission maxima at 355 nm and 430 nm, respectively. This reagent is useful for investigating enzyme activity and dynamics in various biological research applications. -
Cathepsin L Inhibitor
Cathepsin L-IN-3 is a selective noncovalent inhibitor of cathepsin L, exhibiting a Ki value of 4.3 nM. This compound effectively modulates cathepsin L activity, making it a valuable tool for studies in cancer biology and inflammation. Its potency and selectivity enable researchers to investigate the role of cathepsin L in various physiological and pathological processes. -
Cathepsin Inhibitor
ABP 25 is an activity-based probe specifically designed to inhibit cathepsin K, demonstrating high potency and selectivity. This reagent enables effective imaging of cathepsin K activity, making it a valuable tool for studying diseases where cathepsin K plays a critical role, such as bone resorption and related pathologies. Its application extends to various research fields, including cancer, osteoporosis, and cardiovascular diseases. -
Cathepsin E Inhibitor
SQ 32056 is a potent inhibitor of cathepsin E, an aspartyl protease involved in various biological processes, including immune response and inflammation. This compound effectively obstructs the pressor response to endothelin, making it a valuable tool for research into cardiovascular and inflammatory diseases. Its applications extend to studying the role of cathepsins in pathological conditions and evaluating therapeutic strategies targeting protease-mediated signaling pathways. -
Cysteine Cathepsin Inhibitor
GB111-NH2 is a potent cysteine cathepsin inhibitor that plays a crucial role in the modulation of proteolytic activity associated with various pathological conditions, including cancer. Its inhibitory action on cathepsins has made it a valuable tool for researchers investigating tumor progression and metastasis. This compound can facilitate the understanding of cysteine cathepsin's role in cancer biology and aid in the development of targeted therapies. -
Cathepsin S Inhibitor
BI-1915 is a selective inhibitor of Cathepsin S, exhibiting an IC50 of 17 nM. This compound is valuable for studying the role of Cathepsin S in autoimmune diseases and may aid in the development of therapeutic strategies targeting these conditions. Its specificity makes it a useful tool for dissecting the biological functions of this enzyme in various research applications. -
Cathepsin C Inhibitor
Cathepsin C-IN-3 is a selective inhibitor of Cathepsin C, demonstrating a potency with an IC50 value of 61.79 nM. This compound effectively inhibits the proliferation of THP-1 and U937 cell lines, with IC50 values of 101.5 nM and 86.5 nM, respectively. Cathepsin C-IN-3 is valuable for studies focused on the role of Cathepsin C in inflammation and immune responses. -
Cathepsin C Inhibitor
Cathepsin C-IN-7 is a selective inhibitor of Cathepsin C, an enzyme implicated in various inflammatory and cancer-related processes. This compound demonstrates significant biological activity in modulating immune responses and has potential applications in the study of primary cancers and cancer metastases. Researchers can utilize Cathepsin C-IN-7 to investigate the role of Cathepsin C in tumor biology and the progression of malignancies. -
Cathepsin K Inhibitor
MV061194 is a selective inhibitor of cathepsin K, exhibiting a human Ki of 2.5 nM. This compound is utilized in research focused on osteoporosis, providing insights into bone resorption processes and potential therapeutic strategies for bone-related disorders. Its specificity and potency make it a valuable tool for studying the role of cathepsin K in various biological contexts. -
Cathepsin
Heterophyllin A is a natural compound that targets cathepsin enzymes. This compound exhibits notable biological activity by inhibiting cathepsin protease activity, making it a valuable reagent for research into proteolytic pathways. Its applications include studies on cellular processes related to protein degradation, as well as potential therapeutic investigations regarding disease states linked to dysregulated cathepsin function. -
Cathepsin B Substrate
Z-Arg-Arg-AMC is a selective substrate for cathepsin B, a cysteine protease involved in various physiological and pathological processes. This compound facilitates the measurement of cathepsin B activity through the release of a freely diffusible fluorophore. It is commonly utilized in biochemical assays to study protease activity, including research on cancer, inflammation, and other diseases associated with altered cathepsin levels. -
Cathepsin K inhibitor
Cathepsin K inhibitor 5 is a selective inhibitor of Cathepsin K, a cysteine protease involved in bone resorption and remodeling. This compound effectively inhibits Cathepsin K activity, making it valuable for studying osteoclast function and bone-related diseases such as osteoporosis. Its use in research can enhance understanding of bone metabolism and aid in the development of novel therapeutic strategies for bone disorders. -
Cathepsin D inhibitor
TB-9 is a potent inhibitor of cathepsin D, cathepsin E, and BACE1, exhibiting IC50 values of 0.0783 nM, 0.724 nM, and 54.2 nM, respectively. This compound shows significant potential in the study of neurodegenerative diseases and cancer, where cathepsin activity is implicated. Its ability to selectively target these enzymes makes TB-9 an important tool for researchers investigating the role of proteases in various biological processes. -
Cathepsin K Inhibitor
Cathepsin K-IN-8 is a potent inhibitor of cathepsin K, an enzyme involved in the degradation of extracellular matrix components. This compound is primarily utilized in research focused on inflammatory diseases such as rheumatoid arthritis and osteoarthritis, as well as conditions like osteoporosis and tumor progression. Its inhibition of cathepsin K allows for the investigation of its role in these pathological processes, making it a valuable tool for studying bone resorption and related disorders. -
peptides
Cathepsin E substrate e is a selective substrate for the enzyme Cathepsin E, designed to facilitate monitoring of its proteolytic activity. This substrate employs a close proximity of a Mca donor and a Dnp acceptor to create a near-complete intramolecular quenching effect in its intact form. Upon cleavage by Cathepsin E, the spatial separation of Mca and Dnp generates a significant increase in fluorescence, making it an effective tool for studying Cathepsin E activity and its role in various biological processes. -
Cathepsin S Inhibitor
BI-1124 is a selective inhibitor of cathepsin S, a cysteine protease involved in various pathological processes, including inflammation and tissue remodeling. This compound demonstrates effective ocular pharmacokinetic-pharmacodynamic properties in rabbit models following topical administration. BI-1124 is primarily utilized in research focused on age-related dry eye disease, making it a valuable tool for exploring therapeutic interventions in ocular health. -
Cathepsin Inhibitor
Z-FG-NHO-Bz is a selective inhibitor of cathepsins, a family of cysteine proteases involved in various biological processes. This compound exhibits significant inhibitory activity against cathepsin B and L, making it a valuable tool for studying their roles in pathological conditions such as cancer and neurodegenerative diseases. Z-FG-NHO-Bz is ideal for research applications focused on proteolytic enzyme regulation and therapeutic intervention. -
Cathepsin K Inhibitor
Dutacatib is a selective inhibitor of cathepsin K with demonstrated antiviral activity against SARS-CoV-2 3CLpro. By inhibiting cathepsin K, it plays a role in ameliorating bone diseases associated with cancer. This compound is valuable for research focused on therapeutic interventions in viral infections and bone-related pathologies in cancer. -
Cathepsin B Substrate
S2160 is a specific substrate for Cathepsin B, designed for use in calorimetric assays. This compound enables the accurate measurement of Cathepsin B activity in various biological samples. Researchers can utilize S2160 to study proteolytic processes and explore the role of Cathepsin B in physiological and pathological conditions. -
Cathepsin E Inhibitor
SQ 32602 is a potent inhibitor of cathepsin E, exhibiting an IC50 value of 88 nM. This compound selectively inhibits cathepsin E activity, making it valuable for research into lysosomal function and proteolytic processes. SQ 32602 is suitable for studies involving cancer biology, autoimmune diseases, and other conditions where cathepsin E modulation may play a critical role. -
Cathepsin Inhibitor
NC 2300 is a selective and orally active inhibitor of cysteine cathepsins, specifically targeting cathepsin B, K, and S with IC50 values of 284, 34.5, and 186 nM, respectively. This compound is particularly useful in the study of diseases related to bone mineral disorders, enabling researchers to explore the role of cathepsins in these conditions and potential therapeutic interventions. -
Cathepsin D Inhibitor
TB-11 is a potent Cathepsin D inhibitor, demonstrating an IC50 of 0.126 nM for Cathepsin D, alongside inhibitory activity of 1.92 nM for Cathepsin E and 48.8 nM for BACE1. This compound is valuable for research focused on tumor biology and the role of cathepsins in cancer progression. Its selectivity and potency make it a useful tool for investigating the therapeutic potential of Cathepsin D inhibition in various oncological studies. -
Cathepsin K Inhibitor
Cathepsin K-IN-9 is a potent and selective inhibitor of Cathepsin K, exhibiting an IC50 of 6.2 nM. It demonstrates remarkable selectivity with IC50 values exceeding 10,000 nM for Cathepsins B, L, and S, providing over 1600-fold selectivity. With its excellent safety profile and metabolic stability, Cathepsin K-IN-9 is suitable for research applications in osteoporosis and other bone resorption-related studies. -
MPro/Cathepsin L Inhibitor
MPI8 is an inhibitor of the major protease of SARS-CoV-2 (MPro) and cathepsin L, exhibiting significant antiviral activity. It functions through dual and selective inhibition of these key proteases, impacting the viral life cycle and host cellular processes. MPI8 is suitable for use in clinical studies targeting COVID-19 and contributes to understanding therapeutic strategies against SARS-CoV-2. -
cathepsin K Inhibitor
BML-244 is a potent inhibitor of cathepsin K, a cysteine proteinase involved in various pathological processes. This compound demonstrates significant biological activity in the context of inflammatory conditions, making it valuable for research applications related to rheumatoid arthritis (RA) and periodontitis. The inhibition of cathepsin K by BML-244 facilitates the exploration of its role in bone resorption and tissue remodeling, contributing to a better understanding of these diseases. -
Cathepsin S Inhibitor
Cathepsin S-IN-1 is a potent inhibitor of Cathepsin S, a cysteine protease involved in the regulation of immune responses and antigen processing. By selectively targeting Cathepsin S, this compound can modulate inflammatory pathways and contribute to studies on autoimmune diseases, cancer, and other pathological conditions linked to protease activity. Its application in research may provide insights into therapeutic strategies aimed at inhibiting Cathepsin S-mediated processes. -
Neutrophil Cathepsin G Inhibitor
MDL 27399 is a selective inhibitor of human neutrophil cathepsin G, exhibiting a Ki value of 7 μM. This compound is instrumental in studying the role of cathepsin G in inflammatory diseases, allowing researchers to explore potential therapeutic avenues for conditions characterized by excessive neutrophil activity. -
Cathepsin D/HSP90 Inhibitor
Tasiamide B is a potent inhibitor of Cathepsin D and HSP90, derived from the marine cyanobacteria Symploca sp. This linear peptide serves as a valuable scaffold for the development of inhibitors targeting aspartic proteases. Tasiamide B has demonstrated significant efficacy in skin cancer studies by effectively interacting with HSP90, highlighting its potential in cancer research and therapeutic applications. -
Cathepsin L Inhibitor
Cathepsin L-IN-6 is a selective inhibitor of cathepsin L, exhibiting an IC50 value of 0.021 μM. It functions by directly binding to cathepsin L, effectively suppressing its enzymatic activity. Additionally, Cathepsin L-IN-6 inhibits pro-inflammatory cytokines IL-6 and IL-8, demonstrating significant anti-inflammatory properties. This compound is particularly relevant for research focused on acute lung injury and related inflammatory conditions. -
Cathepsin Inhibitor
LV-320 is a potent uncompetitive inhibitor of cathepsin ATG4B, exhibiting an IC50 of 24.5 μM and a Kd of 16 μM. This compound effectively inhibits the enzymatic activity of ATG4B, thereby obstructing autophagic flux in cellular environments. Due to its stability and low toxicity, LV-320 is suitable for in vivo applications, making it a valuable tool for research on autophagy-related pathways. -
Cathepsin B Inhibitor
(Rac)-Z-FA-FMK is a potent inhibitor of cathepsin B, exhibiting a Ki value of 1.5 μM. This compound also inhibits multiple caspases, specifically caspases 2, 3, 6, 7, and 9, with IC50 values ranging from 6.147 to 110.7 μM. Additionally, (Rac)-Z-FA-FMK demonstrates antiviral activity by inhibiting the main protease involved in SARS-CoV-2 replication with an IC50 of 11.39 μM. It further attenuates the increase in IL-1β levels induced by LPS and represses NF-κB transactivation in macrophages, making it useful for research in inflammation and viral pathogenesis. -
Cathepsin L/JAK Inhibitor
Dual Cathepsin L/JAK-IN-1 is a dual inhibitor targeting Cathepsin L (CTSL) and Janus kinases (JAK), exhibiting IC50 values of 0.68 μM for CTSL, 337.1 nM for JAK1, 5.251 nM for JAK2, 27.29 nM for JAK3, and 172.6 nM for TYK2. This compound effectively inhibits the activation of key signaling pathways, including MAPK, NF-κB, and JAK/STAT, thereby providing substantial anti-inflammatory effects. Dual Cathepsin L/JAK-IN-1 is useful for investigating mechanisms underlying acute lung injury (ALI) and other inflammatory conditions. -
Cathepsin Inhibitor
TS-24 is a selective inhibitor of cathepsin S, demonstrating an IC50 value of 4.3 μM. This compound has been shown to exhibit radiosensitizing effects in wild-type BRCA1 and triple-negative breast cancer (TNBC) xenograft models, primarily by inducing apoptotic pathways. TS-24 is suitable for research applications focused on cancer therapeutic development and understanding cathepsin-mediated biological processes. -
Cathepsin B/CANP Inhibitor
NCO-700 is a potent dual inhibitor of cathepsin B and calcium-activated neutral protease (CANP), exhibiting IC50 values of 0.8 μM and 46 μM, respectively. This compound effectively reduces myocardial fibrin degradation by inhibiting protease activity and demonstrates significant anti-tumor effects on hormone-independent cancer cells, including prostate cancer, by inducing apoptosis. NCO-700 serves as a valuable tool for investigating mechanisms underlying myocardial ischemia and exploring novel treatments for refractory hormone-independent tumors. -
Cathepsin L inhibitor
Z-FY-CHO (Z-Phe-Tyr-CHO) is a potent and specific inhibitor of cathepsin L (CTSL), a lysosomal cysteine protease involved in protein degradation and various pathological processes. It is commonly used as a tool compound in studies of CTSL-related functions and diseases. -
Cysteine Protease
Cathepsin B, Bovine spleen is a cysteine protease that plays a critical role in various forms of programmed cell death, including apoptosis, pyroptosis, ferroptosis, necroptosis, and autophagic cell death. This enzyme is instrumental in research applications focused on understanding cellular mechanisms of death and disease progression. Additionally, it serves as a valuable tool for investigating proteolytic processes in both physiological and pathological contexts. -
Cathepsin C Inhibitor
Verducatib is an orally active inhibitor of cathepsin C, also known as Dipeptidyl Peptidase I (DPP1). By inhibiting the activation of neutrophil serine proteases, Verducatib restores the balance of proteases and inhibitors, thereby reducing pulmonary inflammation and enhancing responses to infection. This compound has demonstrated efficacy in decreasing the frequency and severity of acute exacerbations in bronchiectasis, while also improving lung function and quality of life. Its safety profile is comparable to placebo, with a slight increase in mild-to-moderate cutaneous adverse events at higher doses, indicating potential for clinical application.

